<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew M Kaunitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA, also known as DepoProvera) is an injectable progestin-only contraceptive that provides highly effective, private, three-month-long reversible contraception. Use of DMPA eliminates the need for daily user action, action near the time of sexual intercourse, and need for partner cooperation.</p><p>This topic will review <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> formulation, patient selection, and use. Related information on counseling about side effects, risks, and benefits is presented separately. This topic will not discuss norethisterone enanthate injections. Related information on other progestin-only contraceptives and contraceptive counseling and selection is presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H2628035646"><span class="h1">FORMULATIONS AND PHARMACOLOGY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is available in two formulations: 150 mg/1 mL for intramuscular injection (available as a generic) and 104 mg/0.65 mL for subcutaneous injection. Either formulation can be given every 3 months (13 weeks) because low solubility of the microcrystals at the injection site allows pharmacologically active drug levels to persist and remain effective for several months [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intramuscular (IM)</strong> – Following a single IM dose of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>, the drug level increases for approximately three weeks, reaching a peak blood concentration of up to 7 ng/mL for a few days [<a href="#rid2">2,3</a>]. The level then declines until it becomes undetectable between 120 and 200 days following injection [<a href="#rid3">3</a>], but there is considerable inter-individual variability in serum levels. Ovulation resumes at DMPA levels &lt;0.1 ng/mL [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous</strong> <strong>(SC)</strong> – The formulation for subcutaneous injection provides slower and more sustained absorption of the progestin than conventional intramuscular <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. This enables a 30 percent lower dose of progestin (104 versus 150 mg) and reduces peak blood levels by half [<a href="#rid4">4</a>] but with the same duration of effect as conventional DMPA. A study of the pharmacokinetic profile of subcutaneous DMPA over one cycle after injection in the upper arm reported injection at this site provided sufficient medroxyprogesterone levels for contraceptive protection [<a href="#rid5">5</a>]. The study included 24 women with body mass index from 18 to 40 kg/m<sup>2</sup>. Compared with intramuscular dosing, subcutaneous injections are associated with more injection site reactions (8.0 versus 0.4 percent) [<a href="#rid6">6</a>]. These reactions have been described as skin dimpling and may represent lipoatrophy; it is uncertain to what degree these skin changes are reversible [<a href="#rid7">7</a>]. SC DMPA is a user-controlled method, which likely contributes to its higher continuation rates compared with the IM formulation [<a href="#rid8">8</a>] (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Local'</a>.)</p><p></p><p>Serum progesterone levels are low (&lt;0.4 ng/mL) for several months following an injection of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> [<a href="#rid1">1</a>]. Estradiol levels vary, but most women have lower levels than normally cycling women [<a href="#rid1">1,9</a>]. Women who have used DMPA for several years have serum estradiol levels between 10 and 92 pg/mL (mean approximately 40 pg/mL) [<a href="#rid1">1</a>]. Although the endometrium becomes atrophic, vasomotor symptoms are uncommon and the vaginal epithelium remains moist and well rugated.</p><p><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is an effective contraceptive method  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). The unintended pregnancy rate in the first year of use is 6 percent [<a href="#rid10">10</a>]. Efficacy data are discussed in detail in the related counseling topic (see  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"</a>). Progestins can prevent pregnancy via several mechanisms. DMPA primarily acts by inhibition of gonadotropin secretion, thereby inhibiting follicular maturation and ovulation [<a href="#rid11">11</a>]. Progestins also cause changes in cervical mucus (thicker and less permeable to sperm) and tubal motility (reduced ciliary action) that are unfavorable to sperm migration, thus inhibiting fertilization. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Efficacy'</a>.)</p><p class="headingAnchor" id="H3698020878"><span class="h1">PATIENT SELECTION</span></p><p class="headingAnchor" id="H800889793"><span class="h2">Women with contraindications to estrogen therapy</span><span class="headingEndMark"> — </span>Although clinicians should familiarize themselves with the contraindications listed on package labeling for all medications they prescribe, progestin-only hormonal methods appear to be appropriate contraceptive choices for many women with relative contraindications to estrogen-containing contraceptives [<a href="#rid12">12</a>]. Many of the contraindications listed in the package insert were established for combined estrogen-progestin oral contraceptives and then extrapolated to progestin-only methods because clinical trials have not evaluated the safety of the latter in women with contraindications to estrogen. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="headingAnchor" id="H1805195423"><span class="h2">Other candidates</span><span class="headingEndMark"> — </span>Most adolescent and adult women can use <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. The Centers for Disease Control and Prevention <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6503a1.htm%3Fs_cid%3Drr6503a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoIMVxNz7qTN91sychfwmBjXnjAf2YtkLNeW%2BABX%2FWfw04tcvgAO1wSmuCs3zXaWpQk%3D&amp;TOPIC_ID=5468" target="_blank">Medical Eligibility Criteria for Contraceptive Use</a> and the World Health Organization <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.who.int%2Freproductivehealth%2Fpublications%2Ffamily_planning%2FMEC-5%2Fen%2F&amp;token=am3d6Dtogt5e88ewNpT1YCltU%2FEFMr%2BhAi4SPVAemsTKqzf2ZgfGe43nM5ICIgmhJ4qumfr5y6dKOrL%2BzojbSN1MkmGldk6kwM6nQNxB6GA%3D&amp;TOPIC_ID=5468" target="_blank">Medical Eligibility Criteria for Contraceptive Use</a> list individual (eg, breastfeeding) and medical conditions that may impact use of nonbarrier contraceptives [<a href="#rid12">12</a>]. The advantages and disadvantages of DMPA use are summarized in the table  (<a class="graphic graphic_table graphicRef88917" href="/d/graphic/88917.html" rel="external">table 1</a>).</p><p><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is a particularly good contraceptive option for adolescent and adult women who meet any of the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Desire a highly effective reversible contraceptive that does not require daily use</p><p class="bulletIndent1"><span class="glyph">●</span>Have a contraindication to, or wish to avoid, an estrogen-containing contraceptive</p><p class="bulletIndent1"><span class="glyph">●</span>Desire or medical indication for eliminating menstrual bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Wish to take advantage of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>'s noncontraceptive benefits (eg, reduction in dysmenorrhea as well as pelvic pain from endometriosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Prefer a private/discreet method of contraception</p><p class="bulletIndent1"><span class="glyph">●</span>May not consistently remember to use types of contraception that require frequent or pericoital administration</p><p class="bulletIndent1"><span class="glyph">●</span>Have difficulty using other forms of contraception</p><p class="bulletIndent1"><span class="glyph">●</span>Have physical or intellectual differences that make other methods difficult to use or remember</p><p></p><p>A comparison of attributes of the various progestin contraceptive methods is presented separately. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Comparison with other progestin-only contraceptives'</a>.)</p><p class="headingAnchor" id="H3320286048"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> should not be used by women with known breast cancer or who are pregnant [<a href="#rid12">12,13</a>]. In addition, DMPA (both doses) is generally avoided in the following adolescent and adult women, as other contraceptive options are available [<a href="#rid12">12,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Women with severe cirrhosis, hepatocellular adenoma, diabetes with nephrosis or vascular complications, hypertension, ischemic heart disease or multiple risk factors for atherosclerotic disease, and some forms of lupus [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained vaginal bleeding [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy planned within the next year, because a delay in return in fertility may occur with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. (See <a class="local">'Return to fertility after discontinuation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term use of corticosteroid therapy in women with a history of, or risk factors for, nontraumatic (frailty) fractures. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current use of aminoglutethimide (usually for the treatment of Cushing's syndrome) because aminoglutethimide may increase metabolism of progestins [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H757485596"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Routine pelvic and breast examinations, blood pressure measurement, and laboratory tests are not required before initiating <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H2540101"><span class="h2">Injection techniques</span><span class="headingEndMark"> — </span>Administration via the subcutaneous (SC) route is less painful than intramuscular (IM) injection and may facilitate off-label patient self-administration [<a href="#rid16">16-19</a>]. Otherwise, the benefits and risks are similar for IM and SC administration.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intramuscular</strong> – Both the 1 mL vial and the 1 mL prefilled syringe of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> should be shaken vigorously just before use to ensure that the dose being administered represents a uniform suspension; 150 mg of DMPA is administered by deep IM injection in the gluteal or deltoid muscle [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous</strong> – The prefilled syringe (0.65 mL) of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> should be shaken vigorously just before use to create a uniform suspension; 104 mg of DMPA is administered by SC injection into the anterior thigh or abdomen. Although off-label use, SC DMPA can be administered in the upper arm for women who prefer this injection site or decline injection into the anterior thigh or abdomen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Self-administration</strong> – Although self-administration is off-label, this approach can enhance access and facilitate timely continuation. Several reports have documented preliminary experience with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> IM and DMPA SC self-administration [<a href="#rid16">16,17,20,21</a>]. A trial that randomly assigned 401 women to either self- or clinic administration of DMPA SC reported significantly higher one-year continuation rates for women who self-administered the drug (69 versus 54 percent for self- versus clinic administered) [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H26226355"><span class="h2">Timing of injections</span><span class="headingEndMark"> — </span>The first <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection can be given at any time once pregnancy has reasonably been excluded  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H6"><span class="h3">Initial injection</span><span class="headingEndMark"> — </span>Although pregnancy should be excluded before initiating contraception  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 2</a>), there is no evidence that inadvertent administration of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> during pregnancy increases the risk of congenital anomalies [<a href="#rid23">23,24</a>]. In the United States Planned Parenthood National Database for 1994 to 1998, 402 DMPA users became pregnant, and many of these women received more than one dose of DMPA while pregnant [<a href="#rid23">23</a>]. No fetal anomalies were reported; however, birth outcome data were incomplete.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First day of menses</strong> – In cycling women, the ideal time to initiate <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is within seven days of the onset of menses. This approach increases the certainty that the patient is not pregnant at the time of injection and prevents ovulation during the first month of use so that back-up contraception is unnecessary [<a href="#rid25">25</a>]. Most women have pharmacologically active drug levels and relatively impermeable cervical mucus within 24 hours after injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quick start</strong> – Several studies have initiated <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> on the day the patient is first seen for contraception, rather than waiting until her next menses begins [<a href="#rid26">26-29</a>], as long as pregnancy can be excluded with reasonable certainty by history or pregnancy testing  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 2</a>). This "same day," "quick start," or "Depo-now" approach facilitates DMPA initiation for many users [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is initiated more than seven days after the first day of the woman's menstrual period and she has had unprotected intercourse during the cycle, clinicians and patients must recognize that there is a small chance of preimplantation or early pregnancy despite a negative pregnancy test prior to the injection. We suggest these women receive emergency contraception if intercourse occurred within the previous 120 hours, and we advise them to use back-up contraception for seven days after DMPA injection [<a href="#rid31">31</a>] since ovulation may occur within 24 hours of the initial injection, and we counsel them to have a repeat pregnancy test in two to three weeks. (See <a class="local">'Need for back-up contraception'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Switching from another method</strong> – Begin <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> while the woman is still using hormonal contraception (pill, patch, ring) and discontinue the other method seven days after the injection  (<a class="graphic graphic_table graphicRef77410" href="/d/graphic/77410.html" rel="external">table 3</a>). Otherwise, a condom or abstinence should be used as a back-up if the first injection is not given within seven days of menses onset.</p><p></p><p class="bulletIndent1">If switching from intrauterine contraception, the injection should be given seven days before removal of the intrauterine device (IUD). Otherwise, switching from an IUD requires consideration of fertilization and implantation from residual sperm in the reproductive tract. Options to prevent these pregnancies include advising the woman to [<a href="#rid15">15</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abstain from sex or use barrier contraception for seven days before removing the IUD and receiving the first <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use emergency contraception at the time of IUD removal.</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Repeat injections</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users should be encouraged to return every 3 months (13 weeks) for repeat injections.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Women who return late for a repeat injection</strong> – Women using injectable birth control who present late for follow-up injections should not be denied repeat injection solely because they are not on time. After a 150 mg injection, ovulation does not occur for at least 14 weeks. In women more than two weeks late for their injection (&gt;15 weeks from the last injection), we suggest a pregnancy test before administering <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> and back-up contraception (or abstinence) for seven days [<a href="#rid11">11</a>]. In the United States, Centers for Disease Control and Prevention guidelines support this approach [<a href="#rid15">15</a>]; however, the package labeling is more conservative and recommends excluding pregnancy prior to reinjection in women more than one week late for their injection or &gt;14 weeks from their last injection.</p><p></p><p class="bulletIndent1">As a result of a study showing that contraceptive efficacy is maintained with a grace period as long as four weeks [<a href="#rid32">32</a>], the World Health Organization adopted a longer grace period in its updated guideline [<a href="#rid33">33</a>]. In this study of 2290 women in developing countries who underwent 13,608 <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> cycles, the pregnancy risk per 100 women-years was statistically similar for users who were "on time" for their injection (0.6, 95% CI 0.33-0.92, 12,508 cycles), users who were two weeks late for their injection (0.0, 95% CI 0.0-1.88, 739 cycles), and users who were four weeks late for their injection (0.4, 95% CI 0.01-2.29, 893 cycles) [<a href="#rid32">32</a>]. A limitation of these data is that more than one-third of the women in the study were lactating, placing them at low baseline risk for conception.</p><p></p><p class="bulletIndent1">Because pregnancy testing may not be readily available in low-resource countries, expanding the grace period to four weeks is reasonable in such settings. In high-resource countries, we continue to encourage women to return on time and allow a two-week grace period, and we require documentation of a negative pregnancy test in women who present more than two weeks (&gt;15 weeks from their last injection).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Women who return early for a repeat injection</strong> – If it is more convenient for a patient to move up the date of her <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection, a repeat injection may be given early [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H1778067924"><span class="h2">Need for back-up contraception</span><span class="headingEndMark"> — </span>Back-up contraception, such as pericoital contraception (eg, male or female condoms, single-size diaphragm), the previously used hormonal method, or abstinence, is indicated for seven days if [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is initiated more than seven days from the onset of the last menstrual period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The woman is postabortion and <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> was not initiated at the time of the abortion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The woman is postpartum, has not had a menstrual period, and (1) is fully breastfeeding and &gt;6 months postpartum or (2) not fully breastfeeding and ≥21 days postpartum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The woman had an IUD removed at the time of her first <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection. In addition, these women are offered emergency contraception if they have had sex within seven days preceding IUD removal.</p><p></p><p class="headingAnchor" id="H2245364292"><span class="h2">Follow-up after injection</span><span class="headingEndMark"> — </span>Other than scheduling visits for repeat <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection, no specific follow-up is required for DMPA users. As with all contraceptive users, clinicians should encourage the patient to contact them anytime to discuss side effects, questions, problems, or desire to change the method [<a href="#rid15">15</a>]. Patients should also be encouraged to contact their health care providers if they have any significant medical issues, such as starting a new medication that could impact contraceptive use.</p><p class="headingAnchor" id="H2511858706"><span class="h1">SYMPTOMS THAT WARRANT EVALUATION</span><span class="headingEndMark"> — </span>Unscheduled bleeding is common in individuals using <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. Other potential side effects and metabolic changes are discussed in related content. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"</a>.)</p><p class="headingAnchor" id="H2206897671"><span class="h2">Heavy uterine bleeding</span><span class="headingEndMark"> — </span>Unscheduled bleeding with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use is common. However, individuals who report very bothersome or heavy uterine bleeding should be evaluated for other causes and treated as indicated. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Menstrual changes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3401614297"><span class="h2">Symptoms for urgent evaluation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users who develop new-onset chest pain, shortness of breath, or deep unilateral leg pain should be evaluated for possible thromboembolic event, including myocardial infarction, pulmonary embolus, and deep venous thrombosis. The absolute increased risk of cardiovascular and thromboembolic events in women using DMPA is unclear. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'</a>.)</p><p class="headingAnchor" id="H7226619"><span class="h1">DISCONTINUATION</span><span class="headingEndMark"> — </span>One-year discontinuation rates range from 40 to 75 percent [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1270312"><span class="h2">Return to fertility after discontinuation</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> does not permanently impact endocrine function, return of fertility may be delayed. Within 10 months of the last injection, 50 percent of women who discontinue DMPA to become pregnant will conceive [<a href="#rid35">35</a>]. However, in a small proportion of women, fertility is not re-established until 18 months after the last injection. The persistence of ovulation suppression following DMPA discontinuation is not related to the duration of use but is related to body weight; women with lower body weights conceive sooner after discontinuing DMPA than women with higher body weights.</p><p>Before initiating <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> contraception, clinicians should counsel candidates about the possible prolonged duration of contraceptive action. Women who may want to become pregnant within the next one or two years should choose an alternative contraceptive.</p><p class="headingAnchor" id="H8"><span class="h2">Switching from DMPA to another method</span><span class="headingEndMark"> — </span>In <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users changing to a new method, it is appropriate to initiate the new method any time but no later than 15 (ideally no later than 14) weeks after the previous injection. This ensures that the woman is not pregnant at the time she initiates a new contraceptive method. Initiation of the new contraceptive method should not be delayed until resumption of menses. Amenorrhea after discontinuing DMPA injections does not mean the woman is protected against pregnancy if she has unprotected intercourse.</p><p class="headingAnchor" id="H764430329"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is associated with relatively high progestin levels [<a href="#rid2">2</a>]. Accordingly, one benefit of DMPA use is the lack of drug interactions compared with some other hormonal contraceptives [<a href="#rid12">12</a>].</p><p>Potential drug interactions of concern:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglutethimide</strong> – As discussed above, use of aminoglutethimide (usually for the treatment of Cushing's syndrome) is contraindicated because aminoglutethimide may increase metabolism of progestins. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8634" href="/d/drug information/8634.html" rel="external">Fosamprenavir</a> – While there is theoretical concern that progestin use could decrease levels of the protease inhibitor fosamprenavir, use of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is acceptable in women taking this medication [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">Efavirenz</a><strong> and rifampicin</strong> – Combination treatment with efavirenz and rifampicin has been reported to increase <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> clearance based on one study of 42 female participants with HIV and tuberculosis co-infection [<a href="#rid36">36</a>]. Until this finding is confirmed by larger trials, UpToDate does not advise a change in dosing schedule for patients receiving combined treatment with efavirenz and rifampicin.</p><p></p><p>Although the United States package insert for <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> also warns against coadministration of DMPA with antiseizure medications, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, or St. John's wort, the Centers for Disease Control and Prevention and the World Health Organization do not support such restriction and list DMPA as having "advantages that generally outweigh theoretical or proven risks" [<a href="#rid12">12,31</a>].</p><p class="headingAnchor" id="H7898424"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2353600971"><span class="h2">Adolescents</span><span class="headingEndMark"> — </span>Rates of oral contraceptive failure and discontinuation can be very high among adolescents. By contrast, <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> provides highly effective and acceptable contraception in this population [<a href="#rid37">37-43</a>].</p><p>A study of postpartum teens found that <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users were more likely to continue their contraception than oral contraceptive users (55 versus 27 percent) and had lower rates of repeat pregnancy (3 versus 24 percent) during a minimum of 12 months follow-up [<a href="#rid44">44</a>]. If the implant or intrauterine devices are not available, appropriate, or acceptable to the patient, DMPA, coupled with condoms for protection against sexually transmitted infections, should be considered the contraceptive of first choice for sexually active teens [<a href="#rid39">39,45</a>].</p><p>The effect of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> on bone mineral density in adolescents is reviewed separately. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p class="headingAnchor" id="H2741972066"><span class="h2">Overweight and obese women</span><span class="headingEndMark"> — </span>Since <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> results in high progestin levels, efficacy is not reduced by high body weight [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity", section on 'Depot medroxyprogesterone acetate'</a>.)</p><p class="headingAnchor" id="H1131681513"><span class="h2">Perimenopausal women</span><span class="headingEndMark"> — </span>There is no age limit to <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use; women can safely continue DMPA injections until they become menopausal [<a href="#rid12">12</a>]. As long-term DMPA users have high rates of amenorrhea, perimenopausal DMPA users may not experience the irregular bleeding that characteristically accompanies the perimenopausal transition. Likewise, such women may not experience vasomotor symptoms because they are suppressed by DMPA use. (See  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes"</a>.)</p><p>The median age of menopause (when contraception is no longer needed) is 51 to 52 years, meaning that 50 percent of women of this age are still ovulatory. By age 55 years, in contrast, at least 80 percent of women are menopausal [<a href="#rid48">48,49</a>]. Therefore, it is reasonable to continue <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> without gonadotropin testing until the patient is in her mid-50s. At that time, contraception can be discontinued.</p><p>Although serum follicle-stimulating hormone (FSH) concentrations increase across the menopausal transition, a single elevated FSH level is not useful in determining menopausal status in any woman because FSH levels vary from cycle to cycle and may fluctuate between the normal premenopausal and postmenopausal ranges [<a href="#rid50">50</a>]. FSH testing is even less useful in <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users because DMPA suppresses FSH production; thus, menopausal DMPA users may have FSH levels in the premenopausal range related to DMPA. These relationships were illustrated in a study of 82 amenorrheic long-term DMPA users age 40 to 55 years who had FSH testing every 90 days immediately before their DMPA injection; 41 percent of women with a high initial FSH level subsequently had a low FSH level [<a href="#rid51">51</a>]. If FSH is measured in a DMPA user ≥age 50 years, the level is most informative of menopausal status if measured immediately before the next DMPA injection is due [<a href="#rid52">52</a>] and is in the menopausal range on two consecutive occasions [<a href="#rid51">51</a>].</p><p>The effect of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> on bone mineral density is discussed separately. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p class="headingAnchor" id="H4035747454"><span class="h2">Postabortion and postpartum women</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> after abortion or delivery, and in breastfeeding women, is discussed separately. (See  <a class="medical medical_review" href="/d/html/109209.html" rel="external">"Contraception: Postabortion", section on 'Depot medroxyprogesterone acetate'</a> and  <a class="medical medical_review" href="/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods"</a>.)</p><p class="headingAnchor" id="H1206441101"><span class="h1">FACTORS IMPACTING COST</span><span class="headingEndMark"> — </span>Cost to the patient varies due to multiple factors, including geographic region, charge for drug, and insurance coverage. Additionally, use of multi-dose vials are typically less expensive than premeasured subcutaneous <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. However, in some regions, uniject vials for self-administration of subcutaneous DMPA are the cheapest source. Clinicians should familiarize themselves with the available formulations in their regions and the relative costs of each.</p><p class="headingAnchor" id="H120667917"><span class="h1">RESOURCES FOR PATIENTS AND CLINICIANS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F260156%2F9780999203705-eng.pdf%3Bjsessionid%3D064933B28FD7DA686554F11CD71436B4%3Fsequence%3D1&amp;token=p4fHVHXlu%2Bu%2FYP2%2BFKb4BsJONCpIozH3i2JXmy5X6jyqFRc6tiCGWvycG%2FdBWNsOH%2Fu79Xv1oufPaVbYNknLGTsTIBJHTRoEizBTCJXmnfCv8Hr4Ps%2FIFlmVvkfsy9IlsHWy3r9DDSaQDQe2xsoS1%2FZHZtclGLqb4nB6rI7Uh48%3D&amp;TOPIC_ID=5468" target="_blank">World Health Organization</a> – Family Planning: A Global Handbook for Providers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.plannedparenthood.org%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAeZ9SXc2ukqt22nAmmnoIhbmjKCcbIKeiWKTXDj94bQ%2F4&amp;TOPIC_ID=5468" target="_blank">Planned Parenthood</a> – A nonprofit organization dedicated to reproductive health with resources for patients and clinicians.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2F&amp;token=h7Ird6MEQJ0ciS3wlIS74wS%2BbqJQEspyaSo36FRNdkGJJnrJaPDlUEGuXmILPu5F&amp;TOPIC_ID=5468" target="_blank">Bedsider</a> – A free website developed by the National Campaign to Prevent Teen and Unplanned Pregnancy, a private nonprofit group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.choiceproject.wustl.edu%2F&amp;token=%2BnVJmPhZ7CoZ6P5TTscsQMEfRjhRSH%2BHYjLFHmNv8MpZBNOY80TFEfWmQJ4v5GVF&amp;TOPIC_ID=5468" target="_blank">CHOICE Project</a> – A free website sponsored by the Washington University School of Medicine in St. Louis that provides resources on contraceptive options and training resources for clinicians.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fyoungwomenshealth.org%2F&amp;token=4ZVQuaw7JPQhsSQn2msmz4V2t0hJWr2nmfMP%2FLbrjZq3BOM8pXRApS0zZOoQmNVZ&amp;TOPIC_ID=5468" target="_blank">Center for Young Women's Health</a> – A free website run by Boston Children's Hospital that addresses reproductive health needs of teens and young adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fbeyondthepill.ucsf.edu%2F&amp;token=E0Md379RCit4rTlR7PWLpRnWL3ZQCq5b3lbJ0%2FB1dPyBLwfyex9AzfdZhbKHBc6o&amp;TOPIC_ID=5468" target="_blank">Beyond the Pill</a> – A free website run by the University of California San Francisco.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sexandu.ca%2F&amp;token=vdCs7dqmABYrTYLl86e3UBvZDVaCgDBYOgHXgKrHwtk%3D&amp;TOPIC_ID=5468" target="_blank">Sex &amp; U</a> – An educational site run by the Society of Obstetricians and Gynaecologists of Canada that includes descriptions of various methods and a tool to help with selection of birth control.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2FPatients&amp;token=IQxLzDq4doJGUgaZgeIY0609e6kP88t%2BkfEnsFxRTPcTSb1%2BMcd%2F6nq0xBC60AQD&amp;TOPIC_ID=5468" target="_blank">ACOG Contraceptive FAQs</a> – American College of Obstetricians and Gynecologists addresses frequently asked questions (FAQs) about <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Ffaqs%2Fprogestin-only-hormonal-birth-control-pill-and-injection&amp;token=%2FS6KWpsqt8HyceNoSKkms3yvMtQUc%2BVCFahhBA7uEx8hZMTYyff3d7l68BW8oXNTZsW78Pu7ElViiA%2Fey%2F2yfI04%2FxaO3EytUMVDzs2YMuMImiG8VBaBeUBTUn0qZ6cD&amp;TOPIC_ID=5468" target="_blank">progestin-only</a> contraception, including <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fprograms%2Flong-acting-reversible-contraception-larc&amp;token=U83nmWJdEnYplmY9VjWreX3HVdeM4iV5pW6eK0VWJFBp3n3w1ajFQOAV2mS7Cgk1PHjvV%2B4Qkzpl360fr4RK8M6MULij1Bk7TNBpJyQfoTk%3D&amp;TOPIC_ID=5468" target="_blank">ACOG LARC Program</a> – American College of Obstetricians and Gynecologists Long-Acting Reversible Contraception Program.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6503a1.htm%3Fs_cid%3Drr6503a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoIMVxNz7qTN91sychfwmBjXnjAf2YtkLNeW%2BABX%2FWfw04tcvgAO1wSmuCs3zXaWpQk%3D&amp;TOPIC_ID=5468" target="_blank">United States Medical Eligibility Criteria (US MEC) for Contraceptive Use</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6504a1.htm%3Fs_cid%3Drr6504a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoI9S6tDFFGkqrofEu6x4BLSnjAf2YtkLNeW%2BABX%2FWfw0wprhImEEGXBTJh4uBFC8ZY%3D&amp;TOPIC_ID=5468" target="_blank">United States Selected Practice Recommendations (US SPR) for Contraceptive Use</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>World Health Organization: <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.who.int%2Freproductivehealth%2Fpublications%2Ffamily_planning%2FMEC-5%2Fen%2F&amp;token=am3d6Dtogt5e88ewNpT1YCltU%2FEFMr%2BhAi4SPVAemsTKqzf2ZgfGe43nM5ICIgmhJ4qumfr5y6dKOrL%2BzojbSN1MkmGldk6kwM6nQNxB6GA%3D&amp;TOPIC_ID=5468" target="_blank">Medical Eligibility Criteria for Contraceptive Use</a>.</p><p></p><p class="headingAnchor" id="H766733471"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H2199344197"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15349.html" rel="external">"Patient education: Choosing birth control (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8419.html" rel="external">"Patient education: Hormonal methods of birth control (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/8421.html" rel="external">"Patient education: Birth control; which method is right for me? (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulation and dosing</strong> – Depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) is highly effective reversible contraceptive  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>) that is available in two formulations: 150 mg/1 mL for intramuscular injection and 104 mg/0.65 mL for subcutaneous injection. Either formulation is given every 3 months (13 weeks). (See <a class="local">'Formulations and pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Most adolescent and adult females can use <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>, including those with relative contraindications to estrogen-containing contraceptives. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1">Individual characteristics (eg, breastfeeding) and medical conditions that may impact patient selection can be found through: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Centers for Disease Control and Prevention <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6503a1.htm%3Fs_cid%3Drr6503a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoIMVxNz7qTN91sychfwmBjXnjAf2YtkLNeW%2BABX%2FWfw04tcvgAO1wSmuCs3zXaWpQk%3D&amp;TOPIC_ID=5468" target="_blank">Medical Eligibility Criteria for Contraceptive Use</a> and </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The World Health Organization <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.who.int%2Freproductivehealth%2Fpublications%2Ffamily_planning%2FMEC-5%2Fen%2F&amp;token=am3d6Dtogt5e88ewNpT1YCltU%2FEFMr%2BhAi4SPVAemsTKqzf2ZgfGe43nM5ICIgmhJ4qumfr5y6dKOrL%2BzojbSN1MkmGldk6kwM6nQNxB6GA%3D&amp;TOPIC_ID=5468" target="_blank">Medical Eligibility Criteria for Contraceptive Use</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Examination not required for </strong><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a><strong> administration</strong> – Routine pelvic and breast examinations, blood pressure measurement, and laboratory tests are not required before initiating DMPA. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation and repeat dosing</strong> – The ideal time to initiate <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is within seven days of the onset of menses or before discontinuing another method of contraception, but it can be started at almost any time. (See <a class="local">'Timing of injections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of repeat injection</strong> – The dose is repeated every 3 months (13 weeks), with up to a 2-week grace period (15 weeks total from prior injection). (See <a class="local">'Repeat injections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>If a repeat dose is missed</strong> – We advise excluding possibility of pregnancy by history  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 2</a>) or performing a pregnancy test before administering <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> in women more than two weeks late for their injection. (See <a class="local">'Repeat injections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for back-up contraception</strong> – In some clinical scenarios, back-up contraception, such as pericoital contraception (eg, male or female condoms, single-size diaphragm), the previously used hormonal method, or abstinence, is indicated for seven days after initial <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection. (See <a class="local">'Need for back-up contraception'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms that warrant evaluation</strong> – <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is generally well tolerated despite the prevalence of unscheduled bleeding. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heavy uterine bleeding</strong> – Unscheduled bleeding is common with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use and generally tolerated. Individuals who report very bothersome or heavy bleeding should be evaluated for other causes and treated as indicated. (See <a class="local">'Heavy uterine bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptoms for urgent evaluation</strong> – Individuals who develop new-onset chest pain, shortness of breath, or deep unilateral leg pain should be evaluated for possible thromboembolic event, including myocardial infarction, pulmonary embolus, and deep venous thrombosis. (See <a class="local">'Symptoms that warrant evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Return of fertility after stopping </strong><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> – Fifty percent of persons who desire pregnancy will be pregnant within 10 months after their last DMPA injection. However, return of fertility may be delayed after discontinuing DMPA; in a small proportion of individuals, fertility is not re-established until 18 months after the last injection. Accordingly, DMPA is generally not advised for those who wish to conceive in the next one to two years. (See <a class="local">'Return to fertility after discontinuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations – </strong>Adolescent, obese, and perimenopausal females are all potential candidates for <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use. DMPA users can safely continue without gonadotropin testing until in their mid-50s. Perimenopausal DMPA users will not experience the bothersome irregular bleeding that characteristically accompanies the perimenopausal transition and may not experience vasomotor symptoms. (See <a class="local">'Special populations'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:381.</a></li><li><a class="nounderline abstract_t">Ortiz A, Hirol M, Stanczyk FZ, et al. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977; 44:32.</a></li><li class="breakAll">DEPO-PROVERA- medroxyprogesterone acetate injection. http://labeling.pfizer.com/ShowLabeling.aspx?id=522 (Accessed on July 11, 2014).</li><li><a class="nounderline abstract_t">Shelton JD, Halpern V. Subcutaneous DMPA: a better lower dose approach. Contraception 2014; 89:341.</a></li><li><a class="nounderline abstract_t">Halpern V, Combes SL, Dorflinger LJ, et al. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. Contraception 2014; 89:31.</a></li><li><a class="nounderline abstract_t">Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009; 80:7.</a></li><li><a class="nounderline abstract_t">Bush J. Sayana Press and a case of likely lipoatrophy. BMJ Sex Reprod Health 2018.</a></li><li><a class="nounderline abstract_t">Curtis KM, Nguyen A, Reeves JA, et al. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate. MMWR Morb Mortal Wkly Rep 2021; 70:739.</a></li><li class="breakAll">Speroff L, Darney PD. Injectable contraception. In: A Clinical Guide for Contraception, Lippincott Williams &amp; Wilkins, Philadelphia 2010.</li><li><a class="nounderline abstract_t">Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</a></li><li><a class="nounderline abstract_t">Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994; 170:1543.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Depo-Provera CI (medroxyprogesterone acetate). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on February 11, 2015).</li><li><a class="nounderline abstract_t">Lundgren S, Lønning PE, Aakvaag A, Kvinnsland S. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1990; 27:101.</a></li><li><a class="nounderline abstract_t">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception 2012; 85:453.</a></li><li><a class="nounderline abstract_t">Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception 2012; 85:458.</a></li><li><a class="nounderline abstract_t">Beasley A, White KO, Cremers S, Westhoff C. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception 2014; 89:352.</a></li><li><a class="nounderline abstract_t">Keith B, Wood S, Tifft S, Hutchings J. Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings. Contraception 2014; 89:344.</a></li><li><a class="nounderline abstract_t">Williams RL, Hensel DJ, Fortenberry JD. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women. Contraception 2013; 88:401.</a></li><li><a class="nounderline abstract_t">Cover J, Ba M, Lim J, et al. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study. Contraception 2017; 96:203.</a></li><li><a class="nounderline abstract_t">Kohn JE, Simons HR, Della Badia L, et al. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception 2018; 97:198.</a></li><li><a class="nounderline abstract_t">Borgatta L, Murthy A, Chuang C, et al. Pregnancies diagnosed during Depo-Provera use. Contraception 2002; 66:169.</a></li><li><a class="nounderline abstract_t">Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005; 73:906.</a></li><li><a class="nounderline abstract_t">Kapp N, Gaffield ME. Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance: a systematic review. Contraception 2013; 87:576.</a></li><li><a class="nounderline abstract_t">Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception 2005; 71:99.</a></li><li><a class="nounderline abstract_t">Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception 2005; 71:395.</a></li><li><a class="nounderline abstract_t">Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA. Contraception 2007; 75:84.</a></li><li><a class="nounderline abstract_t">Rickert VI, Tiezzi L, Lipshutz J, et al. Depo Now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007; 40:22.</a></li><li><a class="nounderline abstract_t">Lopez LM, Newmann SJ, Grimes DA, et al. Immediate start of hormonal contraceptives for contraception. Cochrane Database Syst Rev 2012; 12:CD006260.</a></li><li class="breakAll">World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th Edition, World Health Organization, 2015.</li><li><a class="nounderline abstract_t">Steiner MJ, Kwok C, Stanback J, et al. Injectable contraception: what should the longest interval be for reinjections? Contraception 2008; 77:410.</a></li><li class="breakAll">World Health Organization Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health. Family Planning: A Global Handbook for Providers (2008 update). Baltimore and Geneva, 2008.</li><li class="breakAll">Goldberg AB, Grimes DA. Injectable contraceptives. In: Contraceptive Technology, 19th ed, Hatcher RA, Trussell J, Nelson AL, et al (Eds), Ardent Media, New York 2007. p.157.</li><li><a class="nounderline abstract_t">Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974; 10:181.</a></li><li><a class="nounderline abstract_t">Mngqibisa R, Kendall MA, Dooley K, et al. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis 2020; 71:517.</a></li><li><a class="nounderline abstract_t">Smith RD, Cromer BA, Hayes MA, et al. Medroxyprogesterone acetate (Depo-Provera) use in adolescents: Uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates. Adolesc Pediatr Gynecol 1993; 8:24.</a></li><li><a class="nounderline abstract_t">Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94:687.</a></li><li><a class="nounderline abstract_t">Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med 1996; 41:407.</a></li><li><a class="nounderline abstract_t">O'Dell CM, Forke CM, Polaneczky MM, et al. Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents. Obstet Gynecol 1998; 91:609.</a></li><li><a class="nounderline abstract_t">Chotnopparatpattara P, Taneepanichskul S. Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception 2000; 62:137.</a></li><li><a class="nounderline abstract_t">Kaunitz AM. Long-acting hormonal contraceptives--indispensable in preventing teen pregnancy. J Adolesc Health 2007; 40:1.</a></li><li><a class="nounderline abstract_t">Tolaymat LL, Kaunitz AM. Long-acting contraceptives in adolescents. Curr Opin Obstet Gynecol 2007; 19:453.</a></li><li><a class="nounderline abstract_t">Templeman CL, Cook V, Goldsmith LJ, et al. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol 2000; 95:770.</a></li><li><a class="nounderline abstract_t">Stevens-Simon C, Kelly L, Kulick R. A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies. Am J Prev Med 2001; 21:60.</a></li><li><a class="nounderline abstract_t">Leiman G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am J Obstet Gynecol 1972; 114:97.</a></li><li><a class="nounderline abstract_t">Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010; 81:487.</a></li><li><a class="nounderline abstract_t">McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985; 103:350.</a></li><li><a class="nounderline abstract_t">Stanford JL, Hartge P, Brinton LA, et al. Factors influencing the age at natural menopause. J Chronic Dis 1987; 40:995.</a></li><li><a class="nounderline abstract_t">Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003; 289:895.</a></li><li><a class="nounderline abstract_t">Juliato CT, Fernandes A, Marchi NM, et al. Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. Contraception 2007; 76:282.</a></li><li><a class="nounderline abstract_t">Pérez-Palacios G, Fernández-Aparicio MA, Medina M, et al. On the mechanism of action of progestins. Acta Endocrinol (Copenh) 1981; 97:320.</a></li></ol></div><div id="topicVersionRevision">Topic 5468 Version 75.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8725700" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacokinetics of depot medroxyprogesterone acetate contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/833262" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/833262" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24267634" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Subcutaneous DMPA: a better lower dose approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993431" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501210" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972355" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sayana Press and a case of likely lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34014910" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34014910" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477680" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contraceptive failure in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178904" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-acting injectable contraception with depot medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2249324" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22079605" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22079602" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656555" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813924" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Home-based administration of Sayana®Press: review and assessment of needs in low-resource settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23294549" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673645" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246818" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384205" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pregnancies diagnosed during Depo-Provera use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206282" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995541" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707558" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15854642" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241834" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185202" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Depo Now: preventing unintended pregnancies among adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235628" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immediate start of hormonal contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235628" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immediate start of hormonal contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477489" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Injectable contraception: what should the longest interval be for reinjections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477489" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Injectable contraception: what should the longest interval be for reinjections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477489" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Injectable contraception: what should the longest interval be for reinjections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4419530" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504342" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Medroxyprogesterone acetate (Depo-Provera) use in adolescents: Uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936897" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8725703" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Use of depot medroxyprogesterone acetate contraception in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540951" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124361" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of depot medroxyprogesterone acetate in Thai adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185200" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-acting hormonal contraceptives--indispensable in preventing teen pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17885461" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-acting contraceptives in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10775745" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Postpartum contraceptive use among adolescent mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11418259" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4637044" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472115" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026083" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Smoking and age at menopause in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3654908" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Factors influencing the age at natural menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588275" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is this woman perimenopausal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900438" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6455041" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : On the mechanism of action of progestins.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
